Tolerability of sorafenib in the treatment of hepatocellular carcinoma (HCC) in patients with Child A and B liver cirrhosis

被引：0
|
作者：
Schuette, K.
Zimmermann, L.
Bornschein, J.
Huster, D.
Csepregi, A.
Malfertheiner, P.
机构：
[1] Univ Magdeburg, D-39106 Magdeburg, Germany
[2] Hufeland Klinikum, Bad Langensalza, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15593
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib
    Nagai, Hidenari
    Kanekawa, Takenori
    Kobayashi, Kojiro
    Mukozu, Takanori
    Matsui, Daigo
    Matsui, Teppei
    Kanayama, Masahiro
    Wakui, Noritaka
    Momiyama, Kouichi
    Shinohara, Mie
    Ishii, Koji
    Igarashi, Yoshinori
    Sumino, Yasukiyo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 223 - 229
  • [22] Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib
    Hidenari Nagai
    Takenori Kanekawa
    Kojiro Kobayashi
    Takanori Mukozu
    Daigo Matsui
    Teppei Matsui
    Masahiro Kanayama
    Noritaka Wakui
    Kouichi Momiyama
    Mie Shinohara
    Koji Ishii
    Yoshinori Igarashi
    Yasukiyo Sumino
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 223 - 229
  • [23] Influence of underlying liver disease on response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Bouattour, M.
    Faivre, S. J.
    Dreyer, C.
    Paradis, V.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] Interferon (IFN), HCV child a cirrhosis and hepatocellular carcinoma (HCC).
    Testino, G
    Andorno, E
    Mondello, R
    Ansaldi, F
    Icardi, G
    Valentini, M
    GASTROENTEROLOGY, 2000, 118 (04) : A1494 - A1494
  • [25] Systemic Therapy with Sorafenib in Patients with HCC and advanced Liver Cirrhosis
    Weinmann, Arndt
    Woerns, Marcus
    Galle, Peter
    Schuchmann, Marcus
    GASTROENTEROLOGE, 2009, 4 (03): : 259 - 260
  • [26] Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis
    Chapin, William J.
    Hwang, Wei-Ting
    Karasic, Thomas B.
    McCarthy, Anne Marie
    Kaplan, David E.
    CANCER MEDICINE, 2023, 12 (01): : 189 - 199
  • [27] Use of sorafenib in recurrent hepatocellular carcinoma (HCC) after liver transplantation
    Chiu, Joanne Wing-Yan
    Yau, Thomas Cheung
    Cheung, Tan To
    Chan, Albert
    Chok, Siu-Ho
    Dai, Wing-Chiu
    Leung, Roland Ching-Yu
    Chan, See-Ching
    Lo, Chung-Mau
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] Early experience of combination treatment of sorafenib and radiotherapy in patients with advanced hepatocellular carcinoma (HCC)
    Seong, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] Sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (HCC): Safety and efficacy in Child-Pugh (CP) class A and B patients
    Pressiani, Tiziana
    Boni, Corrado
    Rimassa, Lorenza
    Labianca, Roberto
    Fagiuoli, Stefano
    Ardizzoni, Andrea
    Foa, Paolo
    Cortesi, Enrico
    Giordano, Laura
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [30] Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation (LT).
    Siegel, A. B.
    Hidalgo, R.
    Tsushima, D.
    Zaretsky, J.
    Emond, J.
    Kato, T.
    Brown, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345